Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights. 

olivia is designed to address two core objectives – centralizing patients’ health data and making that data accessible and actionable through AI. The app enables patients to bring their health information into one unified platform. Patients can connect directly to over 1,000 health systems through electronic health record (EHR) integration, sync data from health devices to track daily metrics, or manually upload health records. olivia then organizes that data into a dynamic timeline where patients can access their records, including lab results, imaging reports, visit summaries, and even deep clinical data such as DICOM images, which can be shared directly with a patient’s care team. olivia’s AI-enabled capabilities allow patients to ask questions about their records, summarize their health information, and receive responses informed by their data; for instance, patients can query, “summarize my health status,” and olivia will provide a clear, concise summary of information in your health data. Additionally, olivia connects to external resources, such as clinicaltrials.gov, to supplement the personalized insights offered from existing health data. 

A few, new features of olivia include:

• Smart Profile Summary: olivia synthesizes a patient’s data – from both their provider and their manual uploads – into an AI-generated smart profile, detailing information such as their clinical diagnoses, family history, medications, and care team.
• AI-enabled Notetaker: olivia can provide patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app’s AI interface.
• Medical Image Sharing: olivia allows patients to easily upload, view, and share their DICOM images in a browser native platform – pixel – with their doctors.
• Health Monitoring: Patients can track symptoms, mood, medications, as well as connect directly with Apple Health and Google Fit to automatically sync sleep, movement, exercise, and heart rate data.
• Direct Data Import: Aggregate health records by connecting directly to a patient’s healthcare provider’s institution to organize, and manage health records in one convenient place, including clinical data, scans, slides, molecular tests, and more.

 
“At Tempus, our goal has always been to improve patient outcomes by harnessing the power of data and AI. Now, as AI becomes increasingly integrated into healthcare, tools like olivia will be essential in helping patients understand and navigate their care,” said Eric Lefkofsky, Founder and CEO of Tempus. “This app goes beyond organizing information; it’s a proactive partner empowering patients to steer their health with confidence and clarity.”

olivia is now available on both iOS and Android. To learn more about olivia and how it can support your health journey, visit oliviahealth.ai.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact and indicated use of olivia and the timing of the availability of the tool. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.